Xingzheng International: Initiates Buy Rating on CSPC Pharmaceutical Group (01093.HK); Innovative Products Expected to Contribute to Growth

date
16/11/2026
Zhitong Finance APP has learned that Industrial Securities International released a research report, initiating coverage on CSPC Pharmaceutical Group (01093.HK) with a "Buy" rating. The firm estimates the company's operating revenue for 2026 to 2028 at RMB 32.046 billion, RMB 30.386 billion, and RMB 32.296 billion, respectively, and net profit attributable to shareholders at RMB 7.249 billion, RMB 5.887 billion, and RMB 6.534 billion, respectively, corresponding to price-to-earnings ratios of 13.34x, 16.43x, and 14.81x based on the closing price on November 12, 2026. The company's finished drug business in 2025 was dragged down by factors such as centralized procurement; in 2026, revenue growth will be driven by the AstraZeneca (AZN.US) licensing deal and increased sales of NBP, while from 2027 onward, new products such as anetumab are expected to continue ramping up sales and become new growth drivers.